National Academies Will Meet to Guide 'Gene Editing' Research
By Lisa M. Krieger,
San Jose Mercury News
| 05. 18. 2015
Untitled Document
The debate over human "gene editing" has moved onto the national stage with a prestigious institute announcing it will hold an international summit this fall to create voluntary standards to guide the use of the controversial technology, first conceived by UC Berkeley molecular biologist Jennifer Doudna.
The landmark conference, announced Monday by the Washington, D.C.-based National Academy of Sciences and National Academy of Medicine, will gather researchers and other experts to review and explore the scientific, ethical and social implications of the practice, which can "cut and paste" gene sequences.
Called CRISPR, an acronym for "clustered regularly interspaced short palindromic repeats," Doudna's tool creates the prospect of a future with less sickness -- but could alter future generations -- influencing human evolution by changing the genes in reproductive cells.
The decision to hold a summit follows last month's news that Chinese researchers created the first genetically modified humans, altering nonviable embryos to try to fix the gene defect that causes beta thalassemia, a blood disease.
Doudna and colleagues, including Stanford University bioethicist Hank Greely, last month called for...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...